<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205438</url>
  </required_header>
  <id_info>
    <org_study_id>13653</org_study_id>
    <secondary_id>H9B-MC-BCDT</secondary_id>
    <nct_id>NCT01205438</nct_id>
  </id_info>
  <brief_title>A Study of LY2127399 in Participants With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two
      different doses of LY2127399 administered in addition to standard of care therapy in
      participants with active SLE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe SLE Flare (SFI)</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Physician's Global Assessment (PGA)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQOL) Domain Scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100.No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1124</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Connective Tissue Disease</condition>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>LY2127399 every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2127399 every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
    <arm_group_label>LY2127399 every 2 weeks</arm_group_label>
    <arm_group_label>LY2127399 every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo every 2 weeks</intervention_name>
    <description>Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo every 4 weeks</intervention_name>
    <description>Administered via subcutaneous injection for 52 weeks.</description>
    <arm_group_label>LY2127399 every 4 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of SLE as defined by American College of Rheumatology (ACR)
             criteria

          -  Have positive antinuclear antibodies (ANA)

          -  Agree not to become pregnant throughout the course of the trial

          -  Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting
             all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)

        Exclusion Criteria:

          -  Have active severe Lupus kidney disease

          -  Have active Central Nervous System or peripheral neurologic disease

          -  Have received intravenous immunoglobulin (IVIg) within 180 days of randomization

          -  Have active or recent infection within 30 days of screening

          -  Have had a serious infection within 90 days of randomization

          -  Have evidence or test positive for Hepatitis B

          -  Have Hepatitis C

          -  Are human immunodeficiency virus (HIV) positive

          -  Have evidence of active or latent tuberculosis (TB)

          -  Presence of significant laboratory abnormalities at screening

          -  Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or
             basal cell or squamous epithelial skin cell that were completely resected with no
             reoccurrence in the 3 yrs prior to randomization

          -  Have received greater than 40 mgs of prednisone or equivalent in the past 30 days

          -  Have changed your dose of antimalarial drug in the past 30 days

          -  Have changed your dose of immunosuppressive drug in the past 90 days

          -  Have previously received rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT -5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern</city>
        <state>Arkansas</state>
        <zip>72104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91941</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lithonia</city>
        <state>Georgia</state>
        <zip>30038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cookeville</city>
        <state>Tennessee</state>
        <zip>38501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campinas</city>
        <zip>13015-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Juiz De Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salvador</city>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cuenca</city>
        <zip>EC010150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guayaquil</city>
        <zip>90110321</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quito</city>
        <zip>17</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gujarat</city>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haryana</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kormangala</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pune</city>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trivandrum</city>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52651</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merida</city>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Otahuhu</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Takapuna</city>
        <zip>622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galati</city>
        <zip>800587</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vigo</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>10630</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Marsa</city>
        <zip>2070</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sfax</city>
        <zip>3029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sousse</city>
        <zip>4000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tunis Monfleury</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wigan</city>
        <state>Lancashire</state>
        <zip>WN6 0LW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Ecuador</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>June 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2018</results_first_posted>
  <disposition_first_submitted>September 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 8, 2014</disposition_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Systemic Lupus Erythematosis</keyword>
  <keyword>Lupus</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>LY2127399</keyword>
  <keyword>Immune System Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>120mg LY2127399 administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
        </group>
        <group group_id="P2">
          <title>LY2127399 Every 4 Weeks</title>
          <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
120mg LY2127399 administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="372"/>
                <participants group_id="P2" count="376"/>
                <participants group_id="P3" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received At Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="374"/>
                <participants group_id="P3" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participated in Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>120mg LY2127399 administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
        </group>
        <group group_id="B2">
          <title>LY2127399 Every 4 Weeks</title>
          <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
120mg LY2127399 administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="372"/>
            <count group_id="B2" value="376"/>
            <count group_id="B3" value="376"/>
            <count group_id="B4" value="1124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="12.41"/>
                    <measurement group_id="B2" value="41.2" spread="12.73"/>
                    <measurement group_id="B3" value="41.9" spread="12.08"/>
                    <measurement group_id="B4" value="41.8" spread="12.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="342"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="349"/>
                    <measurement group_id="B4" value="1037"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="741"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ecuador</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-dsDNA Antibody Level</title>
          <units>International Unit / Milliliter (IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.8" spread="118.17"/>
                    <measurement group_id="B2" value="110.6" spread="113.51"/>
                    <measurement group_id="B3" value="112.0" spread="116.60"/>
                    <measurement group_id="B4" value="113.1" spread="116.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA-SLEDAI) Score</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="4.07"/>
                    <measurement group_id="B2" value="10.4" spread="4.17"/>
                    <measurement group_id="B3" value="9.8" spread="3.28"/>
                    <measurement group_id="B4" value="10.2" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment (PGA) Score</title>
          <description>PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity.Scores are presented from 0 to 100. No worsening is defined as increase of ≥0.3 points.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="15.45"/>
                    <measurement group_id="B2" value="46.8" spread="15.60"/>
                    <measurement group_id="B3" value="44.9" spread="16.57"/>
                    <measurement group_id="B4" value="46.3" spread="15.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At Least One BILAG A or Two BILAG B Disease Activity Scores</title>
          <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
The sum of participants in all Categories for the Measure does not equal the Overall Number of Baseline Participants in the Arm/Group because not all participants will have at least one BILAG A or Two BILAG B Disease Activity scores.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time of Onset of Lupus</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.36" spread="8.500"/>
                    <measurement group_id="B2" value="7.94" spread="7.615"/>
                    <measurement group_id="B3" value="7.74" spread="7.078"/>
                    <measurement group_id="B4" value="8.01" spread="7.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lupus Quality of Life (LupusQOL) Domain Scores</title>
          <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
          <population>All enrolled participants with LupusQOL baseline data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="24.98"/>
                    <measurement group_id="B2" value="59.1" spread="25.13"/>
                    <measurement group_id="B3" value="56.9" spread="26.17"/>
                    <measurement group_id="B4" value="58.4" spread="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="25.19"/>
                    <measurement group_id="B2" value="66.7" spread="23.99"/>
                    <measurement group_id="B3" value="64.6" spread="26.22"/>
                    <measurement group_id="B4" value="65.7" spread="25.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Image</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="338"/>
                    <count group_id="B2" value="343"/>
                    <count group_id="B3" value="342"/>
                    <count group_id="B4" value="1023"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="28.99"/>
                    <measurement group_id="B2" value="63.2" spread="27.67"/>
                    <measurement group_id="B3" value="61.9" spread="29.20"/>
                    <measurement group_id="B4" value="62.1" spread="28.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="28.40"/>
                    <measurement group_id="B2" value="56.9" spread="26.75"/>
                    <measurement group_id="B3" value="53.6" spread="28.62"/>
                    <measurement group_id="B4" value="55.5" spread="27.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="30.37"/>
                    <measurement group_id="B2" value="62.1" spread="28.69"/>
                    <measurement group_id="B3" value="59.0" spread="30.92"/>
                    <measurement group_id="B4" value="60.8" spread="30.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="26.39"/>
                    <measurement group_id="B2" value="54.4" spread="25.54"/>
                    <measurement group_id="B3" value="53.4" spread="27.14"/>
                    <measurement group_id="B4" value="54.6" spread="26.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intimate Relationships</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="316"/>
                    <count group_id="B3" value="320"/>
                    <count group_id="B4" value="950"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="33.92"/>
                    <measurement group_id="B2" value="63.3" spread="31.53"/>
                    <measurement group_id="B3" value="56.8" spread="34.21"/>
                    <measurement group_id="B4" value="58.8" spread="33.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden to Others</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                    <count group_id="B2" value="364"/>
                    <count group_id="B3" value="365"/>
                    <count group_id="B4" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="30.70"/>
                    <measurement group_id="B2" value="51.9" spread="30.31"/>
                    <measurement group_id="B3" value="49.3" spread="32.39"/>
                    <measurement group_id="B4" value="51.3" spread="31.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Fatigue Inventory (BFI) Score</title>
          <description>BFI is a participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="372"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="376"/>
                    <count group_id="B4" value="1124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="2.57"/>
                    <measurement group_id="B2" value="5.6" spread="2.81"/>
                    <measurement group_id="B3" value="5.6" spread="2.81"/>
                    <measurement group_id="B4" value="5.6" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</title>
        <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</title>
          <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
          <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="34.8"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</title>
        <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intention to treat (ITT), only participants receiving a prednisone or equivalent dose of more than 7.5 mg/day at baseline are included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</title>
          <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit.</description>
          <population>Intention to treat (ITT), only participants receiving a prednisone or equivalent dose of more than 7.5 mg/day at baseline are included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</title>
        <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</title>
          <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
          <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>International Units (IU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" spread="65.31"/>
                    <measurement group_id="O2" value="-26.4" spread="64.13"/>
                    <measurement group_id="O3" value="-7.0" spread="56.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</title>
        <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</title>
          <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="4.17"/>
                    <measurement group_id="O2" value="10.4" spread="4.01"/>
                    <measurement group_id="O3" value="9.8" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.57"/>
                    <measurement group_id="O2" value="-4.7" spread="4.62"/>
                    <measurement group_id="O3" value="-3.6" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe SLE Flare (SFI)</title>
        <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Zero participants analyzed. Time to first severe SLE flare data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe SLE Flare (SFI)</title>
          <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
          <population>Zero participants analyzed. Time to first severe SLE flare data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Physician's Global Assessment (PGA)</title>
        <description>PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Physician's Global Assessment (PGA)</title>
          <description>PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
          <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="21.28"/>
                    <measurement group_id="O2" value="-19.2" spread="23.13"/>
                    <measurement group_id="O3" value="-15.1" spread="23.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQOL) Domain Scores</title>
        <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQOL) Domain Scores</title>
          <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
          <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="26.42"/>
                    <measurement group_id="O2" value="66.2" spread="28.01"/>
                    <measurement group_id="O3" value="70.7" spread="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="27.03"/>
                    <measurement group_id="O2" value="72.3" spread="27.72"/>
                    <measurement group_id="O3" value="74.0" spread="28.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Image</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="27.79"/>
                    <measurement group_id="O2" value="72.8" spread="27.60"/>
                    <measurement group_id="O3" value="73.1" spread="29.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="28.98"/>
                    <measurement group_id="O2" value="67.5" spread="29.78"/>
                    <measurement group_id="O3" value="71.4" spread="29.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="30.04"/>
                    <measurement group_id="O2" value="70.7" spread="31.71"/>
                    <measurement group_id="O3" value="73.2" spread="33.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="26.23"/>
                    <measurement group_id="O2" value="62.4" spread="28.17"/>
                    <measurement group_id="O3" value="69.3" spread="26.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intimate Relationships</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="33.39"/>
                    <measurement group_id="O2" value="66.1" spread="33.81"/>
                    <measurement group_id="O3" value="72.4" spread="31.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden to Others</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" spread="32.89"/>
                    <measurement group_id="O2" value="63.7" spread="31.06"/>
                    <measurement group_id="O3" value="69.2" spread="31.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</title>
        <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100.No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</title>
          <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100.No worsening defined as increase of ≤ 0.30 points from Baseline.</description>
          <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.Non-responder imputation (NRI) included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="37.8"/>
                    <measurement group_id="O3" value="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</title>
        <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</title>
          <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
          <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="352"/>
                <count group_id="O3" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.09"/>
                    <measurement group_id="O2" value="-0.5" spread="2.91"/>
                    <measurement group_id="O3" value="-0.5" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</title>
        <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Zero participants analyzed. Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE flare data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</title>
          <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
          <population>Zero participants analyzed. Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE flare data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</title>
        <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intention to treat (ITT), only participants receiving a prednisone or equivalent dose of more than 2.5 mg/day at baseline are included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</title>
          <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
          <population>Intention to treat (ITT), only participants receiving a prednisone or equivalent dose of more than 2.5 mg/day at baseline are included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</title>
        <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</title>
          <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <population>Intention to treat (ITT), Last observation carried (LOCF). LOCF endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="367"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="4.62"/>
                    <measurement group_id="O2" value="-4.8" spread="4.69"/>
                    <measurement group_id="O3" value="-3.7" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</title>
        <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</title>
          <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.</description>
          <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="374"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</title>
        <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug. Non-responder imputation (NRI) included.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Weeks</title>
            <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</title>
          <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
          <population>Intention to treat (ITT), all randomized participants who received at least one dose of study drug. Non-responder imputation (NRI) included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="34.8"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants who received at least 1 dose of study drug. For gender specific events, only occurring in male or female subjects, the number of subjects exposed has been adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug</description>
        </group>
        <group group_id="E2">
          <title>LY2127399 Every 4 Weeks</title>
          <description>During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
        </group>
        <group group_id="E4">
          <title>LY2127399 Every 2 Weeks, Follow Up</title>
          <description>24-48 weeks post last dose for participants receiving LY2127399 every 2 weeks during the Treatment Period.</description>
        </group>
        <group group_id="E5">
          <title>LY2127399 Every 4 Wks, Follow Up</title>
          <description>24-48 weeks post last dose for participants receiving LY2127399 every 4 weeks during the Treatment Period.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Follow Up</title>
          <description>24-48 weeks post last dose for participants receiving placebo during the Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="374"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="376"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Accommodation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lupus hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vagina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urethral polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lupus pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Shrinking lung syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Butterfly rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="249" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="374"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="376"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="374"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="371"/>
                <counts group_id="E2" events="30" subjects_affected="21" subjects_at_risk="374"/>
                <counts group_id="E3" events="37" subjects_affected="32" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="374"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="371"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="374"/>
                <counts group_id="E3" events="42" subjects_affected="35" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="374"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="12" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="374"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="35" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="374"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="374"/>
                <counts group_id="E3" events="28" subjects_affected="22" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="374"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="371"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="374"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="371"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="374"/>
                <counts group_id="E3" events="41" subjects_affected="32" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="371"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="374"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="58" subjects_at_risk="371"/>
                <counts group_id="E2" events="60" subjects_affected="44" subjects_at_risk="374"/>
                <counts group_id="E3" events="63" subjects_affected="45" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="80" subjects_affected="53" subjects_at_risk="371"/>
                <counts group_id="E2" events="81" subjects_affected="60" subjects_at_risk="374"/>
                <counts group_id="E3" events="86" subjects_affected="63" subjects_at_risk="376"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="344"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="371"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="374"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="374"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="374"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="371"/>
                <counts group_id="E2" events="50" subjects_affected="37" subjects_at_risk="374"/>
                <counts group_id="E3" events="52" subjects_affected="34" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="374"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="374"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="371"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="374"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="374"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="376"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="374"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="376"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to product program termination, not all analyses were completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

